Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

PhaseBio Pharmaceuticals, Inc. PHASQ OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
31/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

PhaseBio Pharmaceuticals, Inc. (PHASQ) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 2 Buy, 3 Hold.

PHASQ Analyst Ratings

Hold
5
Ratings
2 Buy
3 Hold
Based on 5 analysts giving stock ratings to PhaseBio Pharmaceuticals, Inc. in the past 3 months
Rating breakdown
Buy
2 40%
Hold
3 60%
40%
Buy
2 analysts
60%
Hold
3 analysts
0%
Sell
0 analysts

People Also View

OTLC
OTLC
Oncotelic Therapeutics, Inc.
$0.04
+1.60%
 CRPOF
CRPOF
Ceapro Inc.
$0.17
-13.04%
 PCSA
PCSA
Processa Pharmaceuticals, Inc.
$2.87
-0.35%
 KLDO
KLDO
Kaleido Biosciences, Inc.
$0.00
+0.00%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message